Palvella Therapeutics’ (PVLA) Buy Rating Reiterated at BTIG Research

BTIG Research reiterated their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research note published on Thursday morning,Benzinga reports. The firm currently has a $192.00 price objective on the stock.

Other equities analysts also recently issued research reports about the company. Chardan Capital increased their price target on Palvella Therapeutics from $110.00 to $174.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Canaccord Genuity Group increased their target price on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Truist Financial increased their price target on Palvella Therapeutics from $105.00 to $190.00 and gave the company a “buy” rating in a report on Monday, December 15th. UBS Group reissued a “buy” rating and set a $143.00 price target on shares of Palvella Therapeutics in a research report on Monday, December 15th. Finally, TD Cowen restated a “buy” rating on shares of Palvella Therapeutics in a report on Tuesday, December 16th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Palvella Therapeutics presently has an average rating of “Buy” and an average price target of $158.69.

Palvella Therapeutics Trading Down 6.4%

Palvella Therapeutics stock opened at $76.69 on Thursday. The firm has a market capitalization of $908.01 million, a PE ratio of -29.16 and a beta of -0.16. Palvella Therapeutics has a 12-month low of $12.60 and a 12-month high of $114.69. The firm has a 50-day moving average price of $96.59 and a 200-day moving average price of $72.61.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.18). As a group, sell-side analysts predict that Palvella Therapeutics will post -3.69 earnings per share for the current fiscal year.

Insider Buying and Selling at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total value of $420,004.26. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have sold 12,906 shares of company stock worth $1,205,980 in the last 90 days. 20.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Palvella Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Aspiriant LLC purchased a new position in Palvella Therapeutics in the third quarter valued at approximately $367,000. Frazier Life Sciences Management L.P. lifted its stake in Palvella Therapeutics by 4.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock valued at $16,283,000 after buying an additional 32,388 shares during the last quarter. Federated Hermes Inc. acquired a new stake in shares of Palvella Therapeutics in the third quarter valued at approximately $21,255,000. XTX Topco Ltd acquired a new stake in Palvella Therapeutics during the 2nd quarter worth $399,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Palvella Therapeutics during the second quarter worth about $37,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.